Cardio Diagnostics Holdings Inc Stock Price, News & Analysis

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) announced that its PrecisionCHD™ test received the Future Digital Award for ‘Best Digital Diagnostics Solution’ from Juniper Research. This award recognizes companies delivering impactful digital health solutions. PrecisionCHD is the second test utilizing Cardio Diagnostics' proprietary AI-driven Integrated Epigenetic-Genetic Engine, which combines epigenetic and genetic biomarkers to detect coronary heart disease (CHD) with over 75% sensitivity. The test is designed to be accessible in various healthcare settings, contributing to democratizing cardiovascular care. CEO Meesha Dogan expressed dedication to innovation and improving patient outcomes. The company aims to develop additional tests for other cardiovascular diseases, enhancing early detection and personalized care.

Cardio Diagnostics Holdings, Inc (NASDAQ: CDIO) is participating in the 22nd Annual Association of Home Office Underwriters (AHOU) Conference from April 16-19, 2023, at The Diplomat Beach Resort, Hollywood, Florida. The conference addresses innovations in life insurance underwriting, especially relating to heart disease, which significantly impacts insurance payouts.

Cardio Diagnostics is a leader in precision cardiovascular medicine, utilizing epigenetics and AI for early detection of cardiovascular diseases, including coronary heart disease (CHD). They will showcase solutions like Epi+Gen CHD and PrecisionCHD, alongside their Actionable Clinical Intelligence™ platform. The CEO, Meesha Dogan, emphasized their commitment to integrating advanced technology in underwriting processes to reduce heart disease-related claims.

Cardio Diagnostics (Nasdaq: CDIO) has announced a strategic engagement with Lifespan.io to enhance awareness and education around heart disease prevention and longevity. This collaboration includes attendance at Lifespan.io's conference, research articles, and discussions on cardiovascular health, epigenetics, and AI-driven diagnostics. Lifespan.io, a nonprofit organization, focuses on extending healthy human lifespan through research and education. The partnership aims to empower individuals to adopt healthier heart practices. Initial resources will be launched in April, with further initiatives planned for the future.

Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) has announced its sponsorship of the Becker’s Hospital Review 13th Annual Meeting from April 3-6, 2023, in Chicago. The event will showcase the company’s new test, PrecisionCHD, at booth #300. This annual meeting will gather over 420 hospital and health system executives to discuss critical healthcare issues. The company focuses on improving cardiovascular disease detection and treatment through its proprietary Integrated Genetic-Epigenetic Engine. CEO Meesha Dogan emphasized the opportunity to showcase innovations aimed at enhancing patient care and reducing costs.

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) has entered a securities purchase agreement with YA II PN, Ltd., securing up to $11.2 million through convertible debentures. The initial closing provided $4.5 million, with plans to utilize the funds for accelerating the adoption of its PrecisionCHD and Epi+Gen CHD clinical tests and developing additional cardiovascular disease tests. CEO Meesha Dogan emphasized that this financing will enhance the company's mission in heart disease prevention. Northland Capital Markets acted as the sole placement agent.

Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, announces the appointment of Dr. Damon Broyles as a strategic advisor. With extensive experience in healthcare innovation and precision medicine, Dr. Broyles will guide Cardio Diagnostics in overcoming challenges and seizing opportunities in cardiovascular disease and precision medicine. He currently leads clinical innovation initiatives at Mercy Technology Services and has played a crucial role in advancing Mercy's precision medicine efforts. CEO Meesha Dogan expresses confidence that Dr. Broyles' leadership will enhance growth and value creation for the company.

Cardio Diagnostics Holdings Inc (Nasdaq: CDIO) announced a significant development as China's Patent Office issued a Notice of Allowance for their patent application titled 'Compositions and Methods for Detecting Predisposition to Cardiovascular Disease.' This patent is exclusively licensed from the University of Iowa Research Foundation and was co-invented by the company's founders. The Notice signifies that the invention meets the patentability requirements, with the patent already granted in the U.S. and Europe. CEO Meesha Dogan expressed excitement over this milestone, highlighting the company's commitment to enhancing healthcare outcomes through a strong intellectual property portfolio.

Cardio Diagnostics Holdings Inc (NASDAQ: CDIO) has launched PrecisionCHD^™, the first integrated epigenetic-genetic blood test aimed at early detection of coronary heart disease (CHD). This test utilizes a proprietary AI-driven engine to enhance sensitivity to over 75% for CHD detection. PrecisionCHD will appeal to clinicians by providing a non-invasive alternative to traditional tests, thus improving accessibility. Following its initial availability for existing customers, a nationwide rollout is expected soon. The test will debut at the American College of Cardiology's annual session from March 4-6, 2023.

Cardio Diagnostics Holdings Inc (Nasdaq: CDIO) announces the introduction of its rapidly accessible coronary heart disease test, PrecisionCHD, at the American College of Cardiology’s 72nd Annual Scientific Session in New Orleans, LA, from March 4-6, 2023. This test leverages epigenetics, genetics, and artificial intelligence to enhance early detection of coronary heart disease. The company aims to improve patient experiences with effective and efficient assessments, reducing wait times significantly compared to traditional methods, which often take weeks or months. CEO Meesha Dogan emphasizes the need for advancements in cardiovascular disease detection and treatment.